Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Enterprise Value (2020 - 2026)

MoonLake Immunotherapeutics' Enterprise Value history spans 7 years, with the latest figure at -$357.9 million for Q1 2026.

  • Quarterly Enterprise Value rose 24.66% to -$357.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$357.9 million through Mar 2026, up 24.66% year-over-year, with the annual reading at -$394.0 million for FY2025, 10.76% up from the prior year.
  • Enterprise Value came in at -$357.9 million for Q1 2026, up from -$394.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of $31.0 million in Q2 2022 to a low of -$537.2 million in Q1 2024.
  • The 5-year median for Enterprise Value is -$420.9 million (2025), against an average of -$331.9 million.
  • The largest YoY upside for Enterprise Value was 2928.04% in 2022 against a maximum downside of 8533.99% in 2022.
  • MoonLake Immunotherapeutics' Enterprise Value stood at -$52.2 million in 2022, then tumbled by 843.98% to -$493.2 million in 2023, then rose by 10.49% to -$441.5 million in 2024, then grew by 10.76% to -$394.0 million in 2025, then rose by 9.15% to -$357.9 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Enterprise Value are -$357.9 million (Q1 2026), -$394.0 million (Q4 2025), and -$378.2 million (Q3 2025).